File Download
  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Seroprevalence of Antibodies to SARS-CoV-2 in Guangdong Province, China between March to June 2020

TitleSeroprevalence of Antibodies to SARS-CoV-2 in Guangdong Province, China between March to June 2020
Authors
KeywordsSARS-CoV-2
Coronavirus disease 2019
Seroprevalence
Guangdong
China
Antibody
Issue Date2021
PublisherMDPI AG. The Journal's web site is located at https://www.mdpi.com/journal/pathogens
Citation
Pathogens, 2021, v. 10 n. 11, article no. 1505 How to Cite?
AbstractGuangdong province, located in South China, is an important economic hub with a large domestic migrant population and was among the earliest areas to report COVID-19 cases outside of Wuhan. We conducted a cross-sectional, age-stratified serosurvey to determine the seroprevalence of antibodies against SARS-CoV-2 after the emergence of COVID-19 in Guangdong. We tested 14,629 residual serum samples that were submitted for clinical testing from 21 prefectures between March and June 2020 for SARS-CoV-2 antibodies using a magnetic particle based chemiluminescent enzyme immunoassay and validated the results using a pseudovirus neutralization assay. We found 21 samples positive for SARS-CoV-2 IgG, resulting in an estimated age- and sex-weighted seroprevalence of 0.15% (95% CI: 0.06–0.24%). The overall age-specific seroprevalence was 0.07% (95% CI: 0.01–0.24%) in persons up to 9 years old, 0.22% (95% CI: 0.03–0.79%) in persons aged 10–19, 0.16% (95% CI: 0.07–0.33%) in persons aged 20–39, 0.13% (95% CI: 0.03–0.33%) in persons aged 40–59 and 0.18% (95% CI: 0.07–0.40%) in persons ≥60 years old. Fourteen (67%) samples had pseudovirus neutralization titers to S-protein, suggesting most of the IgG-positive samples were true-positives. Seroprevalence of antibodies to SARS-CoV-2 was low, indicating that there were no hidden epidemics during this period. Vaccination is urgently needed to increase population immunity to SARS-CoV-2.
Persistent Identifierhttp://hdl.handle.net/10722/309068
ISSN
2020 Impact Factor: 3.492
2020 SCImago Journal Rankings: 0.984
PubMed Central ID
ISI Accession Number ID

 

DC FieldValueLanguage
dc.contributor.authorXiao, C-
dc.contributor.authorLeung, NHL-
dc.contributor.authorCheng, Y-
dc.contributor.authorLei, H-
dc.contributor.authorLing, S-
dc.contributor.authorLin, X-
dc.contributor.authorTao, R-
dc.contributor.authorHuang, X-
dc.contributor.authorGuan, W-
dc.contributor.authorYang, Z-
dc.contributor.authorCowling, BJ-
dc.contributor.authorZanin, M-
dc.contributor.authorWong, SS-
dc.date.accessioned2021-12-14T01:40:09Z-
dc.date.available2021-12-14T01:40:09Z-
dc.date.issued2021-
dc.identifier.citationPathogens, 2021, v. 10 n. 11, article no. 1505-
dc.identifier.issn2076-0817-
dc.identifier.urihttp://hdl.handle.net/10722/309068-
dc.description.abstractGuangdong province, located in South China, is an important economic hub with a large domestic migrant population and was among the earliest areas to report COVID-19 cases outside of Wuhan. We conducted a cross-sectional, age-stratified serosurvey to determine the seroprevalence of antibodies against SARS-CoV-2 after the emergence of COVID-19 in Guangdong. We tested 14,629 residual serum samples that were submitted for clinical testing from 21 prefectures between March and June 2020 for SARS-CoV-2 antibodies using a magnetic particle based chemiluminescent enzyme immunoassay and validated the results using a pseudovirus neutralization assay. We found 21 samples positive for SARS-CoV-2 IgG, resulting in an estimated age- and sex-weighted seroprevalence of 0.15% (95% CI: 0.06–0.24%). The overall age-specific seroprevalence was 0.07% (95% CI: 0.01–0.24%) in persons up to 9 years old, 0.22% (95% CI: 0.03–0.79%) in persons aged 10–19, 0.16% (95% CI: 0.07–0.33%) in persons aged 20–39, 0.13% (95% CI: 0.03–0.33%) in persons aged 40–59 and 0.18% (95% CI: 0.07–0.40%) in persons ≥60 years old. Fourteen (67%) samples had pseudovirus neutralization titers to S-protein, suggesting most of the IgG-positive samples were true-positives. Seroprevalence of antibodies to SARS-CoV-2 was low, indicating that there were no hidden epidemics during this period. Vaccination is urgently needed to increase population immunity to SARS-CoV-2.-
dc.languageeng-
dc.publisherMDPI AG. The Journal's web site is located at https://www.mdpi.com/journal/pathogens-
dc.relation.ispartofPathogens-
dc.rightsThis work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.-
dc.subjectSARS-CoV-2-
dc.subjectCoronavirus disease 2019-
dc.subjectSeroprevalence-
dc.subjectGuangdong-
dc.subjectChina-
dc.subjectAntibody-
dc.titleSeroprevalence of Antibodies to SARS-CoV-2 in Guangdong Province, China between March to June 2020-
dc.typeArticle-
dc.identifier.emailLeung, NHL: nanleung@connect.hku.hk-
dc.identifier.emailCowling, BJ: bcowling@hku.hk-
dc.identifier.authorityLeung, NHL=rp02637-
dc.identifier.authorityCowling, BJ=rp01326-
dc.description.naturepublished_or_final_version-
dc.identifier.doi10.3390/pathogens10111505-
dc.identifier.pmid34832661-
dc.identifier.pmcidPMC8619097-
dc.identifier.scopuseid_2-s2.0-85119898474-
dc.identifier.hkuros330787-
dc.identifier.volume10-
dc.identifier.issue11-
dc.identifier.spagearticle no. 1505-
dc.identifier.epagearticle no. 1505-
dc.identifier.isiWOS:000725167200001-
dc.publisher.placeSwitzerland-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats